Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Umezawa R, Ito Y, Wakita A, Nakamura S, Okamoto H, Takahashi K, Inaba K, Murakami N, Igaki H, Jingu K, Itami J. How Much Was the Elective Lymph Node Region Covered in Involved-Field Radiation Therapy for Locally Advanced Pancreatic Cancer? Evaluation of Overlap Between Gross Target Volume and Celiac Artery-Superior Mesenteric Artery Lymph Node Regions. Adv Radiat Oncol 2020;5:377-387. [PMID: 32529131 PMCID: PMC7278027 DOI: 10.1016/j.adro.2019.08.014] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2019] [Revised: 08/24/2019] [Accepted: 08/27/2019] [Indexed: 12/26/2022] Open

For:	Umezawa R, Ito Y, Wakita A, Nakamura S, Okamoto H, Takahashi K, Inaba K, Murakami N, Igaki H, Jingu K, Itami J. How Much Was the Elective Lymph Node Region Covered in Involved-Field Radiation Therapy for Locally Advanced Pancreatic Cancer? Evaluation of Overlap Between Gross Target Volume and Celiac Artery-Superior Mesenteric Artery Lymph Node Regions. Adv Radiat Oncol 2020;5:377-387. [PMID: 32529131 PMCID: PMC7278027 DOI: 10.1016/j.adro.2019.08.014] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2019] [Revised: 08/24/2019] [Accepted: 08/27/2019] [Indexed: 12/26/2022] Open

Number

Cited by Other Article(s)

Versteijne E, van Dam JL, Besselink MG, Groot Koerkamp B, Homs MYV, Wilmink JW, van Eijck CH, van Tienhoven G. Reply to W. Attaallah, A. Jain et al, and P. Mroczkowski et al. J Clin Oncol 2022;40:3348-3351. [PMID: 35737926 DOI: 10.1200/jco.22.00875] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open

Affiliation(s)

Eva Versteijne Eva Versteijne, MD, PhD, Amsterdam UMC Location Vrije Universiteit Amsterdam, Department of Radiation Oncology, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands; Jacob L. van Dam, MD, Erasmus MC Cancer Institute, Department of Surgery, Rotterdam, the Netherlands; Marc G. Besselink, MD, PhD, Amsterdam UMC Location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands; Bas Groot Koerkamp, MD, PhD, Erasmus MC Cancer Institute, Department of Surgery, Rotterdam, the Netherlands; Marjolein Y.V. Homs, MD, PhD, Erasmus MC Cancer Institute, Department of Medical Oncology, Rotterdam, the Netherlands; Johanna W. Wilmink, MD, PhD, Amsterdam UMC Location University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands; Casper H. van Eijck, MD, PhD, Erasmus MC Cancer Institute, Department of Surgery, Rotterdam, the Netherlands; and Geertjan van Tienhoven, MD, PhD, Amsterdam UMC Location University of Amsterdam, Department of Radiation Oncology, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands
Jacob L van Dam Eva Versteijne, MD, PhD, Amsterdam UMC Location Vrije Universiteit Amsterdam, Department of Radiation Oncology, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands; Jacob L. van Dam, MD, Erasmus MC Cancer Institute, Department of Surgery, Rotterdam, the Netherlands; Marc G. Besselink, MD, PhD, Amsterdam UMC Location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands; Bas Groot Koerkamp, MD, PhD, Erasmus MC Cancer Institute, Department of Surgery, Rotterdam, the Netherlands; Marjolein Y.V. Homs, MD, PhD, Erasmus MC Cancer Institute, Department of Medical Oncology, Rotterdam, the Netherlands; Johanna W. Wilmink, MD, PhD, Amsterdam UMC Location University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands; Casper H. van Eijck, MD, PhD, Erasmus MC Cancer Institute, Department of Surgery, Rotterdam, the Netherlands; and Geertjan van Tienhoven, MD, PhD, Amsterdam UMC Location University of Amsterdam, Department of Radiation Oncology, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands
Marc G Besselink Eva Versteijne, MD, PhD, Amsterdam UMC Location Vrije Universiteit Amsterdam, Department of Radiation Oncology, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands; Jacob L. van Dam, MD, Erasmus MC Cancer Institute, Department of Surgery, Rotterdam, the Netherlands; Marc G. Besselink, MD, PhD, Amsterdam UMC Location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands; Bas Groot Koerkamp, MD, PhD, Erasmus MC Cancer Institute, Department of Surgery, Rotterdam, the Netherlands; Marjolein Y.V. Homs, MD, PhD, Erasmus MC Cancer Institute, Department of Medical Oncology, Rotterdam, the Netherlands; Johanna W. Wilmink, MD, PhD, Amsterdam UMC Location University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands; Casper H. van Eijck, MD, PhD, Erasmus MC Cancer Institute, Department of Surgery, Rotterdam, the Netherlands; and Geertjan van Tienhoven, MD, PhD, Amsterdam UMC Location University of Amsterdam, Department of Radiation Oncology, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands
Bas Groot Koerkamp Eva Versteijne, MD, PhD, Amsterdam UMC Location Vrije Universiteit Amsterdam, Department of Radiation Oncology, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands; Jacob L. van Dam, MD, Erasmus MC Cancer Institute, Department of Surgery, Rotterdam, the Netherlands; Marc G. Besselink, MD, PhD, Amsterdam UMC Location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands; Bas Groot Koerkamp, MD, PhD, Erasmus MC Cancer Institute, Department of Surgery, Rotterdam, the Netherlands; Marjolein Y.V. Homs, MD, PhD, Erasmus MC Cancer Institute, Department of Medical Oncology, Rotterdam, the Netherlands; Johanna W. Wilmink, MD, PhD, Amsterdam UMC Location University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands; Casper H. van Eijck, MD, PhD, Erasmus MC Cancer Institute, Department of Surgery, Rotterdam, the Netherlands; and Geertjan van Tienhoven, MD, PhD, Amsterdam UMC Location University of Amsterdam, Department of Radiation Oncology, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands
Marjolein Y V Homs Eva Versteijne, MD, PhD, Amsterdam UMC Location Vrije Universiteit Amsterdam, Department of Radiation Oncology, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands; Jacob L. van Dam, MD, Erasmus MC Cancer Institute, Department of Surgery, Rotterdam, the Netherlands; Marc G. Besselink, MD, PhD, Amsterdam UMC Location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands; Bas Groot Koerkamp, MD, PhD, Erasmus MC Cancer Institute, Department of Surgery, Rotterdam, the Netherlands; Marjolein Y.V. Homs, MD, PhD, Erasmus MC Cancer Institute, Department of Medical Oncology, Rotterdam, the Netherlands; Johanna W. Wilmink, MD, PhD, Amsterdam UMC Location University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands; Casper H. van Eijck, MD, PhD, Erasmus MC Cancer Institute, Department of Surgery, Rotterdam, the Netherlands; and Geertjan van Tienhoven, MD, PhD, Amsterdam UMC Location University of Amsterdam, Department of Radiation Oncology, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands
Johanna W Wilmink Eva Versteijne, MD, PhD, Amsterdam UMC Location Vrije Universiteit Amsterdam, Department of Radiation Oncology, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands; Jacob L. van Dam, MD, Erasmus MC Cancer Institute, Department of Surgery, Rotterdam, the Netherlands; Marc G. Besselink, MD, PhD, Amsterdam UMC Location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands; Bas Groot Koerkamp, MD, PhD, Erasmus MC Cancer Institute, Department of Surgery, Rotterdam, the Netherlands; Marjolein Y.V. Homs, MD, PhD, Erasmus MC Cancer Institute, Department of Medical Oncology, Rotterdam, the Netherlands; Johanna W. Wilmink, MD, PhD, Amsterdam UMC Location University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands; Casper H. van Eijck, MD, PhD, Erasmus MC Cancer Institute, Department of Surgery, Rotterdam, the Netherlands; and Geertjan van Tienhoven, MD, PhD, Amsterdam UMC Location University of Amsterdam, Department of Radiation Oncology, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands
Casper H van Eijck Eva Versteijne, MD, PhD, Amsterdam UMC Location Vrije Universiteit Amsterdam, Department of Radiation Oncology, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands; Jacob L. van Dam, MD, Erasmus MC Cancer Institute, Department of Surgery, Rotterdam, the Netherlands; Marc G. Besselink, MD, PhD, Amsterdam UMC Location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands; Bas Groot Koerkamp, MD, PhD, Erasmus MC Cancer Institute, Department of Surgery, Rotterdam, the Netherlands; Marjolein Y.V. Homs, MD, PhD, Erasmus MC Cancer Institute, Department of Medical Oncology, Rotterdam, the Netherlands; Johanna W. Wilmink, MD, PhD, Amsterdam UMC Location University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands; Casper H. van Eijck, MD, PhD, Erasmus MC Cancer Institute, Department of Surgery, Rotterdam, the Netherlands; and Geertjan van Tienhoven, MD, PhD, Amsterdam UMC Location University of Amsterdam, Department of Radiation Oncology, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands
Geertjan van Tienhoven Eva Versteijne, MD, PhD, Amsterdam UMC Location Vrije Universiteit Amsterdam, Department of Radiation Oncology, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands; Jacob L. van Dam, MD, Erasmus MC Cancer Institute, Department of Surgery, Rotterdam, the Netherlands; Marc G. Besselink, MD, PhD, Amsterdam UMC Location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands; Bas Groot Koerkamp, MD, PhD, Erasmus MC Cancer Institute, Department of Surgery, Rotterdam, the Netherlands; Marjolein Y.V. Homs, MD, PhD, Erasmus MC Cancer Institute, Department of Medical Oncology, Rotterdam, the Netherlands; Johanna W. Wilmink, MD, PhD, Amsterdam UMC Location University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands; Casper H. van Eijck, MD, PhD, Erasmus MC Cancer Institute, Department of Surgery, Rotterdam, the Netherlands; and Geertjan van Tienhoven, MD, PhD, Amsterdam UMC Location University of Amsterdam, Department of Radiation Oncology, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands

Collapse